Additional Benefits of Photodynamic Diagnosis in Bladder Cancer Treatment

What is it about?

This study evaluated the benefits of using photodynamic diagnosis (PDD) with blue-light cystoscopy in transurethral resection (TURBT) for primary non-muscle-invasive bladder cancer (NMIBC) based on the International Bladder Cancer Group (IBCG)-defined progression and subsequent pathological pathways. The study found that PDD use decreased the risk of bladder cancer recurrence and IBCG-defined progression, but not conventionally defined progression. PDD use improved several oncological endpoints, including IBCG-defined progression-free survival, grade-up-free survival, and high-grade bladder-free survival. Sankey diagrams showed that patients with primary or first-recurrence Ta low-grade tumours did not have bladder recurrence or progression in the PDD-TURBT group, while some patients in the WL-TURBT group developed recurrence after treatment. The study concluded that PDD use in NMIBC patients significantly reduced the risk of IBCG-defined progression and demonstrated possible differences in pathological pathways after the initial TURBT between the two groups.

Featured Image

Why is it important?

This research is important because it evaluates the additional oncological benefit of photodynamic diagnosis (PDD) using blue-light cystoscopy in transurethral resection (TURBT) for primary non-muscle-invasive bladder cancer (NMIBC) based on the International Bladder Cancer Group (IBCG)-defined progression and the subsequent pathological pathways. The study found that PDD use decreased the risk of bladder cancer recurrence and IBCG-defined progression, whereas no significant difference was noted in conventionally defined outcomes. This information can help guide clinical decision-making and improve patient outcomes. Key Takeaways: 1. PDD use decreased the risk of bladder cancer recurrence and IBCG-defined progression, whereas no significant difference was noted in conventionally defined outcomes. 2. PDD use reduced the risk of stage-up and grade-up in patients with NMIBC. 3. Sankey diagrams showed that repeated recurrence could be prevented by PDD use and that patients with primary Ta low-grade tumour and first-recurrence Ta low-grade tumour did not have bladder recurrence or progression, while some of those in the WL-TURBT group developed recurrence after treatment. 4. This study highlights the importance of considering IBCG-defined progression and subsequent pathological pathways when evaluating the effectiveness of PDD in the treatment of NMIBC.